danazol (Danocrine)
Jump to navigation
Jump to search
Introduction
Tradename: Danocrine.
Indications
- endometriosis
- fibrocystic breast disease
- hereditary angioedema
- precocious puberty[4]
- gynecomastia
- menorrhagia[4]
Dosage
- endometriosis: start 400 mg PO BID, then titrate downward
- fibrocystic breast disease: 50-300 mg PO BID
- hereditary angioedema: 400-600 mg/day divided BID-TID
Tabs: 50, 100, 200 mg.
Adverse effects
(generally reversible)
- common (> 10%)
- weight gain, oily skin, acne, hirsutism, deepening of voice, amenorrhea, breakthrough bleeding, irregular menses, breast shrinkage
- less common (1-10%)
- edema, virilization, weakness, decreased estrogen
- uncommon (< 1%)
- photosensitivity, vaginitis (monilial & atrophic), testicular atrophy, enlargement of clitoris, bleeding gums, carpal tunnel syndrome, cholestatic jaundice, benign intracranial hypertension, pancreatitis
- other
Drug interactions
- inhibits cyt P450 3A4
- may increase levels of drugs metabolized by cyt P450 3A4
- increased anticoagulant effect of warfarin
Laboratory
Mechanism of action
More general terms
Additional terms
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 403
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ 4.0 4.1 4.2 Deprecated Reference
- ↑ Department of Veterans Affairs, VA National Formulary